4DMedical Ltd ( (AU:4DX) ) has shared an update.
4DMedical Limited has announced a strategic review resulting in a cost reduction program expected to save $6.5 million annually. This initiative, alongside a successful $13.9 million capital raise, aims to optimize operational efficiency without impacting revenue growth or key milestones. The company is focusing on expanding its commercial activities, particularly in the US, and advancing its CT:VQ™ technology post-FDA clearance. Changes in company leadership include the appointment of Chris Cox as Interim CFO and Hamish George as Company Secretary. These measures are intended to safeguard the company’s long-term growth and financial stability.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global medical technology company specializing in advanced respiratory care solutions. Utilizing cutting-edge imaging and AI-powered technologies, the company offers innovative tools for the early and precise diagnosis of respiratory diseases. Its patented XV Technology® and FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) provide detailed insights into lung function, enhancing the ability of physicians to detect and monitor lung abnormalities. 4DMedical’s solutions are designed to integrate seamlessly into existing hospital systems through a Software as a Service (SaaS) model.
YTD Price Performance: -25.00%
Average Trading Volume: 927,646
Technical Sentiment Signal: Buy
Current Market Cap: A$153.7M
Find detailed analytics on 4DX stock on TipRanks’ Stock Analysis page.